🔥 6 key compounds

Fat Loss Peptides

Fat loss peptides target adipose tissue through various mechanisms including lipolysis stimulation, metabolic rate enhancement, and adipogenesis inhibition. Research focuses on specificity for fat tissue to avoid the side effects of earlier weight-loss approaches.

LipolysisMetabolicAdipose TissueBody Composition
6
Key compounds documented
Adipose
Primary target tissue
AOD-9604
Most selective compound
β3-AR
Common receptor target

Overview

Fat loss peptides represent a scientifically interesting category because they attempt to achieve selective effects on adipose tissue. Unlike broad stimulants, many of these compounds were designed to specifically target fat cell receptors or metabolic pathways involved in fat breakdown.

AOD-9604 is a fragment of human growth hormone (amino acids 176-191) that was specifically developed to retain the fat-burning properties of GH while eliminating its diabetogenic effects. Research has shown it can stimulate lipolysis and inhibit lipogenesis without affecting insulin sensitivity.

GLP-1 receptor agonists like semaglutide represent a newer generation of metabolic peptides that have shown remarkable efficacy in both research settings and clinical trials for obesity management.

Key Compounds

AOD-9604

GH Fragment

Fragment 176-191 of human GH. Specifically targets β3-adrenergic receptors on fat cells to stimulate lipolysis without IGF-1 elevation.

LipolysisSelectiveNo IGF-1

Tesamorelin

GHRH

FDA-approved GHRH analogue shown to reduce visceral adipose tissue. Extensively studied in HIV-associated lipodystrophy and metabolic syndrome.

Visceral fatFDA approvedMetabolic

Fragment 176-191

GH Fragment

The C-terminal fragment of hGH that mimics the metabolic actions of GH on adipose tissue without the growth-promoting effects.

Fat oxidationAnti-lipogenicSelective

CJC-1295

GHRH

Long-acting GHRH analogue that, through GH stimulation, enhances lipolysis and improves body composition in research models.

GH mediatedBody compositionLong-acting

Semaglutide

GLP-1

GLP-1 receptor agonist with remarkable clinical evidence for weight management. Reduces appetite and caloric intake through central and peripheral mechanisms.

Appetite suppressionClinical evidenceMetabolic

Tirzepatide

GLP-1/GIP

Dual GIP and GLP-1 receptor agonist showing superior efficacy in weight loss trials compared to single-receptor agonists.

Dual actionSuperior efficacyFDA approved

Mechanism of Action

1

Lipolysis Activation

Peptides activate hormone-sensitive lipase and adipose triglyceride lipase in fat cells, breaking down stored triglycerides into free fatty acids.

2

Receptor-Mediated Signaling

β3-adrenergic receptor activation in brown adipose tissue and β3-AR on white fat cells stimulates thermogenesis and lipolysis respectively.

3

Lipogenesis Inhibition

Some peptides downregulate key enzymes involved in fat synthesis including fatty acid synthase and acetyl-CoA carboxylase.

4

Central Appetite Regulation

GLP-1 and GIP receptor agonists act on hypothalamic circuits to reduce hunger signaling and increase satiety.

Research Applications

⚖️

Obesity Research

Investigating mechanisms and interventions for reducing excess adipose tissue in various models.

🔬

Metabolic Syndrome Studies

Examining relationships between adiposity, insulin resistance, and cardiovascular risk.

🧬

Body Composition Research

Studying selective fat reduction while preserving lean muscle mass.

💊

Drug Development

Many compounds in this class are templates for pharmaceutical drug development for obesity.

⚠️

Research Information Only

This content is provided for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any health-related decisions.